Article Text

PDF
Sildenafil - from POM to P

Statistics from Altmetric.com

Generic name: Sildenafil

Brand name: Viagra Connect

Formulation: 50mg film-coated tablets

Market authorisation holder: Pfizer Consumer Healthcare Ltd

Indication: Viagra Connect is indicated in adult men with erectile dysfunction

Dose: 50mg approximately one hour before sexual activity (maximum 50mg daily)

Classification: Pharmacy medicine (P)

Key learning points

  • Sildenafil 50mg tablets (Viagra Connect) are available as a pharmacy medicine for use by men aged ≥18 years who have erectile dysfunction.

  • In fixed-dose studies three times as many men reported that 50mg sildenafil improved their erections compared with placebo (74% vs. 25%).

  • The market authorisation holder (Pfizer Consumer Healthcare Ltd.) has published training materials and a checklist to help pharmacists assess whether a patient is suitable for Viagra Connect.

  • As part of the assessment process, pharmacists are advised to take into consideration a patient’s cardiovascular health, other medical conditions and all medicines that the patient is taking.

  • The market authorisation holder advises that men should make an appointment with their GP within 6 months of first purchasing Viagra Connect.

  • Retail price: £19.99 (4 tablets), £34.99 (8 tablets).

Background

Phosphodiesterase-5 (PDE-5) inhibitors (e.g. sildenafil) are a first-line option for the management of erectile dysfunction.1 Sildenafil (25mg, 50mg and 100mg) has been available as a prescription only medicine (POM) since 1998. Following an application from the licence-holder (Pfizer Consumer Healthcare) to reclassify sildenafil as a medicine that can be supplied without prescription from pharmacies under the supervision of a pharmacist, the Medicines and Healthcare products Regulatory Agency (MHRA) has licensed a product containing 50mg sildenafil as a pharmacy medicine (P).2-4

Efficacy

As the formulations of the P and POM sildenafil products …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.